Recombinant Rat CD40/TNFRSF5 Fc Chimera Protein, CF
R&D Systems, part of Bio-Techne | Catalog # 8229-CD
Key Product Details
Source
Accession #
Structure / Form
Conjugate
Applications
Product Specifications
Source
Rat CD40 (Val24-Arg193) Accession # Q4QQW2 |
IEGRMDP | Mouse IgG2A (Glu98-Lys330) |
N-terminus | C-terminus |
Purity
Endotoxin Level
N-terminal Sequence Analysis
Predicted Molecular Mass
SDS-PAGE
Activity
The ED50 for this effect is 0.1-0.6 μg/mL.
Scientific Data Images for Recombinant Rat CD40/TNFRSF5 Fc Chimera Protein, CF
Recombinant Rat CD40/TNFRSF5 Fc Chimera Protein Bioactivity
Recombinant Rat CD40/TNFRSF5 Fc Chimera (Catalog # 8229-CD) inhibits CD40 Ligand-induced proliferation of mouse B cells. The ED50 for this effect is 0.1-0.6 μg/mL.Formulation, Preparation and Storage
8229-CD
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS and Trehalose. |
Reconstitution |
Reconstitute at 200 μg/mL in sterile PBS.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: CD40/TNFRSF5
CD40, also known as TNFRSF5, is an approximately 32-35 kDa type I transmembrane glycoprotein member of the TNF receptor superfamily. The extracellular domain of rat CD40 shares 81% and 56% aa sequence identity with mouse and human CD40, respectively. Multiple rat CD40 splice variants have been reported including soluble isoforms. CD40 is expressed on the surface of B cells, dendritic cells, macrophages, monocytes and platelets, as well as endothelial and epithelial cells (1, 2). Interaction of CD40 with its ligand, CD40 Ligand, leads to the aggregation of CD40 molecules resulting in the initiation of intracellular signaling in both CD40 and CD40 Ligand expressing cells (3). CD40 ligation by CD40 Ligand promotes B cell activation and T cell-dependent humoral responses (4, 5). CD40 serves multiple functions in both hematopoietic and epithelial cancers and is a target for tumor immunotherapy (6, 7). Dysregulation of CD40/CD40 Ligand expression and interactions contributes to the immune deficiency associated with HIV infection and AIDS (8, 9). It is also implicated in the pathology of multiple cardiovascular diseases including atherosclerosis, atherothrombosis, and restenosis (10, 11).
References
- van Kooten, C. and J. Banchereau (1997) Curr. Opin. Immunol. 9:330.
- Schonbeck, U. et al. (1997) J. Biol. Chem. 272:19569.
- Eissner, G. et al. (2004) Cytokine Growth Factor Rev. 15:353.
- Rickert, R.C. et al. (2011) Immunol. Rev. 244:115.
- Elgueta, R. et al. (2009) Immunol. Rev. 229:152.
- Loskog, A.S. and A.G. Eliopoulos (2009) Semin. Immunol. 21:301.
- Hangalapura, B.N. et al. (2012) J. Gene Med. 14:416.
- Kornbluth, R.S. (2000) J. Leukoc. Biol. 68:373.
- Chougnet, C. (2003) J. Leukoc. Biol. 74:702.
- Pamukcu, B. et al. (2011) Ann. Med. 43:331.
- Hassan, G.S. et al. (2012) Immunobiology 217:521.
Alternate Names
Gene Symbol
UniProt
Additional CD40/TNFRSF5 Products
Product Documents for Recombinant Rat CD40/TNFRSF5 Fc Chimera Protein, CF
Product Specific Notices for Recombinant Rat CD40/TNFRSF5 Fc Chimera Protein, CF
For research use only